Last reviewed · How we verify
GR1501 low dose
GR1501 is a low-dose drug that targets a specific molecular pathway.
At a glance
| Generic name | GR1501 low dose |
|---|---|
| Sponsor | Genrix (Shanghai) Biopharmaceutical Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 3 |
Mechanism of action
However, the exact mechanism of action for GR1501 is not well-documented, and further research is needed to fully understand its effects.
Approved indications
Common side effects
Key clinical trials
- Study of Efficacy and Safety of GR1501 in Patients with Radiographic Axial Spondyloarthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |